Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial

Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera RF, Unizony SH, Collinson N (2016)

Publication Type: Conference contribution

Publication year: 2016

Journal

Arthritis and Rheumatology Wiley

Book Volume: 68

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Harvard University US United States (USA) (US) Istituto di ricovero e cura a carattere scientifico (IRCCS) IT Italy (IT) University of Groningen / Rijksuniversiteit Groningen NL Netherlands (NL) Southend Hospital GB United Kingdom (GB) Roche Products Limited and Roche Diagnostics Limited GB United Kingdom (GB) Universitat de Barcelona (UB) / University of Barcelona ES Spain (ES) Genentech Inc. US United States (USA) (US) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven BE Belgium (BE) Hospital for Special Surgery (HSS) US United States (USA) (US)

How to cite

APA:

Stone, J.H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D.,... Collinson, N. (2016). Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial.

MLA:

Stone, John H., et al. "Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial." 2016.

BibTeX: Download